Bioneer
Daily close in US$ at the latest USD/KRW close. Source: KRX via FinanceDataReader.
Bioneer Corporation makes laboratory tools and reagents, such as DNA synthesis products, PCR instruments, and automated nucleic-acid extraction equipment, that scientists use to study and work with genes.
Its customers include universities, government research institutes, and corporate laboratories across Korea and more than fifty countries worldwide. Listed on KOSDAQ, Korea's tech-focused small-cap board, the company also operates molecular-diagnostics and RNA-based drug-development businesses alongside its core life-science research products.
Summary is AI-generated and may contain errors · figures from DART filings
Bioneer conducts its probiotics business through a subsidiary called AcesBiome and its RNA-interference drug development through a subsidiary called Theragnosis, giving it a multi-entity corporate structure.
Bioneer in five facts
What does Bioneer do?
Bioneer Corporation makes laboratory tools and reagents, such as DNA synthesis products, PCR instruments, and automated nucleic-acid extraction equipment, that scientists use to study and work with genes.
Where is Bioneer listed and in which sector?
Bioneer (Korean name: 바이오니아) trades under KRX code 064550 on KOSDAQ, the Korea Exchange's board for smaller and growth companies. It is classified in the Health Care sector, Pharmaceuticals.
How large is Bioneer?
Its market capitalisation was US$151.4M on 2026-10-21, which puts it in this site's small-cap group. US$ amounts are converted from won at 1 USD ≈ ₩1,325 (2026-10-21).
What were Bioneer's latest annual revenue and operating profit?
For fiscal year 2025, Bioneer reported revenue of US$249.2M, operating profit of US$11.5M and net income of US$1.3M, per its annual report on DART (data retrieved from DART on 2026-09-17). Revenue was up 12.3% on the previous year.
Where does this data come from?
Financial statements and filings come from DART, Korea's official corporate-filing system. Share prices, market capitalisation and trading status come from KRX. Company summaries are AI-generated from the filings and may contain errors; financial figures are mapped directly from DART.
Data sources and last updated
- Filings and financial statements
- DART (dart.fss.or.kr), Korea's official corporate-filing system
- Prices, market cap, trading status
- KRX (Korea Exchange), via FinanceDataReader
- Latest annual financials
- Fiscal year 2025, data retrieved from DART on 2026-09-17
- Share price and market cap
- Close of 2026-10-21
- Currency
- US$, converted from won at 1 USD ≈ ₩1,325 (2026-10-21 close)
- Company data updated
- 2026-10-21
- Company summary
- AI-generated from filings; may contain errors. Information only, not investment advice.
- Report on securities held by executives/major shareholdersOct 12
- Report on securities held by executives/major shareholdersOct 12
- Operating results (consolidated) (preliminary) (fair disclosure)
Bioneer filed provisional (unaudited) consolidated results for Q1 2026: revenue of US$55.5M (+10.75% year on year), an operating loss of US$516K (from a profit a year earlier) and a net loss of US$2.05M (from a profit a year earlier).
Earnings · Apr 30 - Change of 30% or more in revenue or profit/loss structure (15% for large companies)
Bioneer reported consolidated results for FY2025: revenue of US$230M (+12.29% year on year), operating profit of US$10.6M (from a loss a year earlier) and net income of US$1.19M (from a loss a year earlier).
Earnings · Feb 27